RT Journal Article
SR Electronic
T1 Prognostic Factors for Gastric Cancer with Cancer Cells in the Peritoneal Cavity
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 2481
OP 2485
VO 36
IS 5
A1 MINORU FUKUCHI
A1 ERITO MOCHIKI
A1 TORU ISHIGURO
A1 TOSHIRO OGURA
A1 JUN SOBAJIMA
A1 YOUICHI KUMAGAI
A1 KEIICHIRO ISHIBASHI
A1 HIDEYUKI ISHIDA
YR 2016
UL http://ar.iiarjournals.org/content/36/5/2481.abstract
AB Aim: To identify the prognostic factors for gastric cancer with positive peritoneal cytology (CY1) or peritoneal metastasis (P1). Patients and Methods: We retrospectively analyzed clinicopathological and survival data of 78 patients who had undergone gastrectomy and/or S-1 based chemotherapy for CY1 or P1 gastric cancer. Results: The median overall survival (OS) did not differ significantly between patients with CY1P0, CY0P1 and CY1P1 disease (24, 17 vs. 14 months, respectively). Among 12 clinicopathological factors, clinical N3 (odds ratio [OR]=2.18; 95% confidence interval [CI]=1.22-4.00; p=0.01) and gastrectomy not performed (OR=1.80; 95% CI=1.29-2.51; p<0.01) were significant independent prognostic factors. The median OS significantly differed between patients who had undergone gastrectomy plus chemotherapy versus chemotherapy alone (22 vs. 10 months, respectively; p<0.01). Conclusion: Gastrectomy and perioperative chemotherapy may both be indicated in CY1 or P1 gastric cancer patients with clinical N0-2.